Peripheral iris thickness associated with ITC in PAC

Article

Peripheral iris thickness is associated with iridotrabecular contact (ITC) in those who have angle closure, according to new research out of Japan.

Peripheral iris thickness is associated with iridotrabecular contact (ITC) in those who have angle closure, according to new research out of Japan.

The investigators prospectively recruited patients with primary angle closure (PAC) and PAC glaucoma addressed with laser peripheral iridotomy (LPI). They performed anterior segment optical coherence tomography (AS-OCT) under light and dark conditions and took scans along the vertical and horizontal axes.

They used software to measure iris thickness at 500 µm (IT500) and 750 µm (IT750) from the scleral spur, maximal iris thickness (MIT) and cross sections of the iris area (I-Area). The investigators defined ITC by ASOCT as the contact between the peripheral iris and angle wall anterior to the scleral spur. They defined the ITC+ group as eyes having ITC in 2 or more quadrants and the ITC- group as eyes having ITC in 0 or 1 quadrant.

The researchers examined 79 eyes of 60 patients; 48 had PAC and 31 had PACG. They found superior ITC in 44 eyes (55.7%), inferior ITC in 48 eyes (60.8%), temporal ITC in 18 eyes (22.8%), and nasal ITC in 16 eyes (20.2%). For analysis, they used the iris parameters of the inferior quadrant, which had the highest prevalence of all the quadrants.

The investigators adjusted for age, sex, pupil size and central anterior chamber depth and found that mean values of IT500 and IT750 were significantly greater in the ITC+ group than in the ITC- group (P + group compared with the ITC- group, per 0.1-unit increase, were 1.9 for IT500 (P = 0.029); 2.0 for IT750 (P = 0.011), 1.4 for MIT (P = 0.244), and 0.97 for I-Area (P = 0.406), they noted.

"In this study, approximately 40% of patients had ITC in two or more quadrants even after LPI, and peripheral iris thickness was considered to be important for angle-closure pathogenesis," the authors wrote. "To arrive at a definitive conclusion, further investigation is necessary in a larger number of cases in the future."

Read the article in Clinical Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.